Compare TXRH & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | BMRN |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.5B |
| IPO Year | 2004 | 1999 |
| Metric | TXRH | BMRN |
|---|---|---|
| Price | $168.86 | $53.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $189.47 | $88.42 |
| AVG Volume (30 Days) | 824.9K | ★ 2.9M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | 12.56 | ★ 59.53 |
| EPS | ★ 6.55 | 2.68 |
| Revenue | ★ $5,833,958,000.00 | $3,094,001,000.00 |
| Revenue This Year | $11.90 | $13.39 |
| Revenue Next Year | $10.41 | $7.57 |
| P/E Ratio | $25.68 | ★ $19.89 |
| Revenue Growth | ★ 14.40 | 12.39 |
| 52 Week Low | $148.73 | $50.76 |
| 52 Week High | $199.99 | $73.51 |
| Indicator | TXRH | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 46.21 |
| Support Level | $164.51 | $52.55 |
| Resistance Level | $178.68 | $54.33 |
| Average True Range (ATR) | 3.14 | 1.24 |
| MACD | -0.41 | -0.17 |
| Stochastic Oscillator | 24.93 | 19.23 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.